Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Debt (2017 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Total Debt for 11 consecutive years, with $309.1 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 2.88% to $309.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $309.1 million through Dec 2025, down 2.88% year-over-year, with the annual reading at $309.1 million for FY2025, 2.88% down from the prior year.
  • Total Debt hit $309.1 million in Q4 2025 for Ani Pharmaceuticals, down from $312.9 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $318.3 million in Q4 2024 to a low of $183.4 million in Q1 2021.
  • Historically, Total Debt has averaged $281.9 million across 5 years, with a median of $286.8 million in 2022.
  • Biggest five-year swings in Total Debt: dropped 8.27% in 2021 and later skyrocketed 56.55% in 2022.
  • Year by year, Total Debt stood at $287.4 million in 2021, then decreased by 0.59% to $285.7 million in 2022, then changed by 0.0% to $285.7 million in 2023, then increased by 11.42% to $318.3 million in 2024, then dropped by 2.88% to $309.1 million in 2025.
  • Business Quant data shows Total Debt for ANIP at $309.1 million in Q4 2025, $312.9 million in Q3 2025, and $314.7 million in Q2 2025.